Retatrutide Research Roundup: What the Studies Show (2026)

The 2023 phase 2 trial

The main primary source in the published human record is Jastreboff and colleagues' 2023 article, "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial," in the New England Journal of Medicine. Its DOI is 10.1056/NEJMoa2301972.

The study was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial. It enrolled 338 adults. Eligible participants had obesity, or overweight plus at least one weight-related condition, and did not have type 2 diabetes. Participants were assigned to one of several retatrutide groups or placebo and were followed through 48 weeks.

The primary endpoint was percentage change in body weight from baseline at week 24. Secondary endpoints included percentage change at week 48 and the proportions of participants reaching prespecified weight-change thresholds. Safety was assessed throughout the trial.

What the phase 2 trial reported

At week 24, the least-squares mean percentage change in body weight ranged from 7.2% to 17.5% reductions across the retatrutide groups, compared with a 1.6% reduction in the placebo group. At week 48, the reported range was 8.7% to 24.2% reductions across retatrutide groups, compared with 2.1% in the placebo group. Larger mean changes were generally seen in the higher assigned groups.

The publication also reported categorical endpoints. At week 48, greater proportions of participants in several retatrutide groups had reached the prespecified 5%, 10%, and 15% weight-change thresholds than in the placebo group.

These were group-level trial results. They were not predictions for an individual, and they do not establish outcomes for different populations, settings, or materials. The study was designed to estimate response, side effects, and safety across assigned groups, not to provide use guidance.

What the safety findings showed

The most common adverse events in the retatrutide groups were gastrointestinal. The authors described them as dose-related and mostly mild to moderate in severity. The publication also reported dose-dependent increases in heart rate that peaked at week 24 and declined afterward.

These findings are part of the evidence, not a footnote to the body-weight results. Phase 2 studies are intended in part to characterize safety signals and inform later research. Longer and larger trials are needed to understand uncommon events, durability, variation among populations, and longer-term benefit-risk questions.

The trial was funded by Eli Lilly, the developer of retatrutide. The publication describes sponsor involvement in study design, oversight, monitoring, data handling, and analysis. That does not invalidate the findings, but it is relevant context when appraising the evidence.

Important limits of the phase 2 evidence

Several boundaries should remain visible when the trial is summarized.

It was one defined population

The trial enrolled adults meeting specific body-mass-index and health criteria and excluded type 2 diabetes. Results should not be generalized beyond the studied population without supporting data.

It was not a head-to-head comparison

The comparator was placebo. The trial did not directly compare retatrutide with semaglutide or tirzepatide. No registered head-to-head trial against those agents has reported as of August 2026.

Forty-eight weeks is not long-term certainty

The study provided controlled observations through 48 weeks, followed by a safety follow-up period. Questions about longer exposure, durability, and rare adverse events require later evidence, and the phase 3 program now supplies part of that.

The investigational drug is not a generic RUO vial

The clinical trial used a sponsor-manufactured investigational product under a regulated protocol. A third-party research material is a different article with different documentation. The trial cannot authenticate a supplier's lot or establish its analytical quality.

What the 2025 Biomolecules review adds

A 2025 review in Biomolecules, available through PubMed Central, synthesized retatrutide's triple-agonist pharmacology and the preclinical and early clinical literature. The article, "Retatrutide: A Game Changer in Obesity Pharmacotherapy," identifies the molecule as an agonist at GLP-1, GIP, and glucagon receptors and discusses how those pathways may contribute to its observed metabolic effects.

The review is useful as a map of the field. It places the phase 2 obesity trial alongside earlier studies and ongoing phase 3 work, and it identifies unresolved questions about long-term evidence. It is not a substitute for the primary trial report. Narrative reviews select, organize, and interpret existing studies, while primary publications provide the methods and results needed for direct appraisal.

Researchers should also separate mechanistic proposals from confirmed causal explanations. A plausible account of how three receptors contribute to an observed endpoint does not prove the precise contribution of each receptor in humans. Multi-agonist pharmacology depends on relative potency, exposure, tissue context, and downstream signaling.

What the phase 3 TRIUMPH trials reported

The TRIUMPH program moved from registration to results during 2026, which is the largest change to the retatrutide evidence base since the phase 2 report.

TRIUMPH-1 (NCT05929066) is an 80-week, randomized, double-blind, placebo-controlled master trial in 2,339 adults with obesity or overweight and at least one weight-related condition, without diabetes, with nested basket trials in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea. Lilly announced topline results on 21 May 2026: mean body-weight reductions at 80 weeks of 19.0%, 25.9%, and 28.3% in the 4 mg, 9 mg, and 12 mg groups against 2.2% for placebo, and 30.3% at 104 weeks in a prespecified 532-participant extension. Discontinuation due to adverse events was 4.1%, 6.9%, and 11.3% across the three doses against 4.9% for placebo. Fuller results, including the two basket trials, were presented at the ADA 86th Scientific Sessions in June 2026.

TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045) reported topline on 23 July 2026. TRIUMPH-2 studied adults with type 2 diabetes and obesity or overweight and reported mean weight reductions of 12.7%, 19.1%, and 20.8% at 80 weeks with A1C reductions up to 1.6%. TRIUMPH-3 randomized 1,949 adults with severe obesity and established cardiovascular disease and reported mean reductions up to 22.6% at 80 weeks. Lilly described these as the fourth and fifth positive phase 3 readouts, and stated it plans to submit a Biologics License Application for US approval in the first quarter of 2027.

Separately, TRANSCEND-T2D-1 reported at ADA in June 2026 and was published in The Lancet the same day. Three points follow from all of this and are worth stating plainly. A submission plan is not an approval. Topline press releases precede peer-reviewed publication, so the detailed data for TRIUMPH-2 and TRIUMPH-3 were still pending as of August 2026. And none of it changes the regulatory status of retatrutide today.

The current position of the development program is tracked in more detail in where the retatrutide phase 3 program stands in 2026.

Is retatrutide legal to buy?

In the United States, retatrutide is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of August 2026. What it is not: an approved drug in any country, a dietary supplement ingredient, or a substance cleared for human or veterinary use in any form.

Three boundaries define the position:

1. Research sale is lawful; human-use marketing is not. Retatrutide is an unapproved new drug under the Federal Food, Drug, and Cosmetic Act, so introducing it into commerce for human use is prohibited. The FDA has warned companies that sold retatrutide labeled "for research purposes" while in fact marketing it to consumers with dosing instructions. The label is not the test. The marketing is.
2. Compounding is closed, not open. The FDA states that retatrutide cannot be used in compounding under federal law, since it is neither a component of an approved drug nor a substance found safe and effective for any condition. No lawful compounded or prescription form exists in the US as of August 2026.
3. Sport is stricter than law. WADA's 2026 Prohibited List prohibits substances with no current approval by any governmental regulatory health authority for human therapeutic use. Retatrutide holds no such approval, so tested athletes should treat it as prohibited regardless of its status as a research chemical.

None of this changes how a supplier like Curo operates. Retatrutide is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy and the responsible intended-use guidance explain what that boundary means in practice.

Where researchers source retatrutide

Sourcing is a separate question from the literature, and this page does not settle it. Curo lists retatrutide (RTA-GLP3) for laboratory research, fulfilled from the United States, with every lot tested by an independent laboratory and every certificate readable without an account. For current pricing, the supplier checks that matter, and how the 2026 phase 3 results have changed the market for this compound, see where the retatrutide phase 3 program stands in 2026.

How to read a retatrutide claim

When a statement about retatrutide appears in an article, supplier page, or social post, classify it before judging it:

1. Molecular claim: Does it describe receptor targets or structure?
2. Mechanistic claim: Is it a hypothesis about downstream biology?
3. Preclinical finding: Was it observed in vitro or in an animal model?
4. Clinical finding: Did it come from a registered human trial, and has that trial been published or only announced?
5. Review conclusion: Is an author synthesizing other studies?
6. Material claim: Does it concern the identity or purity of a particular supplier lot?

These categories require different evidence. A clinical paper can support a trial result, but not a third-party vial's identity. A chromatogram can support a lot's purity profile, but not a clinical outcome.

Connecting literature review to material verification

For laboratory sourcing, a researcher should move from the literature question to lot-specific evidence. HPLC supports a chromatographic purity assessment under the stated method. LC-MS supports identity by comparing observed mass with the expected value, which for retatrutide is near 4,731 g/mol. Endotoxin testing addresses a separate contamination attribute.

Curo provides these records through its certificate-of-analysis lookup. The COA and batch-documentation guide explains how to match analytical records with a physical lot, and the research peptide catalog shows materials in their intended laboratory context.

Analytical testing does not make a research material equivalent to the investigational drug used in clinical trials. It addresses the narrower, necessary questions of what the lot contains and what its reported quality attributes are.

What the evidence supports today

As of August 2026, the record supports describing retatrutide as an investigational GIP, GLP-1, and glucagon receptor agonist with published phase 2 findings, five reported positive phase 3 readouts, one phase 3 publication in The Lancet, and a stated US submission plan for the first quarter of 2027. The 2025 review helps organize the pharmacology and the development picture.

The record does not support treating retatrutide as approved, assuming that receptor count proves superiority, converting trial results into personal guidance, or using clinical publications to validate a third-party RUO lot. Those conclusions require evidence the cited studies were not designed to provide.

Further reading

The phase 3 program is now the fastest-moving part of the retatrutide picture, including trial completions, publication status, and what the submission timeline means. The current position is tracked in where the retatrutide phase 3 program stands in 2026.

For how retatrutide sits against the two approved incretin agents at the receptor level, see the comparison of retatrutide, tirzepatide, and semaglutide.

For the documentation side of sourcing any research peptide, see the guide to purity claims and COA batch documentation.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2301972.

Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metabolism. 2022. PMID 35985340.

Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. "Retatrutide: A Game Changer in Obesity Pharmacotherapy." Biomolecules. 2025;15(6):796. DOI: 10.3390/biom15060796.

Eli Lilly and Company. TRIUMPH-1 topline results, 21 May 2026; ADA presentation, 6 June 2026; TRIUMPH-2 and TRIUMPH-3 topline results, 23 July 2026.

US Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Updated 2026.

ClinicalTrials.gov. NCT05929066, NCT05929079, NCT05882045.

Frequently asked questions

What is retatrutide?

Retatrutide (LY3437943) is an investigational 39-amino-acid synthetic peptide that agonizes the GIP, GLP-1, and glucagon receptors in a single molecule. Eli Lilly developed it. As of August 2026 no regulator has approved it anywhere, and outside clinical trials it is sold only as a research chemical for laboratory use.

Is retatrutide legal?

In the United States, retatrutide is legal to purchase as a research chemical for laboratory use. It is not a controlled substance as of August 2026. It is an unapproved new drug, so selling or marketing it for human use is prohibited under the Federal Food, Drug, and Cosmetic Act, and the FDA states it cannot be used in compounding.

Where can a researcher buy retatrutide?

From suppliers that publish lot-specific, independently issued certificates of analysis and operate as identifiable companies. Curo lists retatrutide (RTA-GLP3) with every lot's certificate published openly. Current pricing and the full supplier checklist are covered in where the retatrutide phase 3 program stands in 2026.

Is retatrutide FDA approved?

No. As of August 2026 retatrutide has no marketing authorization in the United States or any other country. Eli Lilly has said it plans to submit a Biologics License Application for US approval in the first quarter of 2027, which is a filing plan and not an approval.

What did the phase 3 TRIUMPH trials report?

TRIUMPH-1 reported mean body-weight reductions of 19.0% to 28.3% at 80 weeks against 2.2% for placebo, in 2,339 participants. TRIUMPH-2 and TRIUMPH-3 reported in July 2026 in adults with type 2 diabetes and with established cardiovascular disease respectively. Detailed peer-reviewed publications for those two were still pending as of August 2026.

What is retatrutide's CAS number and molecular weight?

Retatrutide carries CAS number 2381089-83-2 with molecular formula C221H342N46O68 and an average molecular weight near 4,731 g/mol. A lot's certificate of analysis should confirm identity by mass spectrometry against that expected value.

Is retatrutide banned in sport?

Treat it as prohibited. WADA's 2026 Prohibited List covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and retatrutide holds no such approval as of August 2026.